Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 66.99% | 57.69% | -99.98% | -145.30% | -207.60% |
| Total Depreciation and Amortization | -82.02% | -92.75% | -74.20% | -36.15% | 34.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.30% | -85.69% | 9,987.01% | 621.51% | 405.08% |
| Change in Net Operating Assets | 156.16% | 338.95% | 407.18% | -134.19% | -146.91% |
| Cash from Operations | 57.68% | 60.38% | -8.57% | -63.62% | -120.47% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -168.56% | -- | -- |
| Total Debt Issued | 16.44% | 28.50% | 155.06% | 79.45% | 84.63% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.10% | 26.23% | 86.51% | 36.55% | 40.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 214.21% | 322.55% | 316.79% | 108.35% | -789.71% |